ClinicalTrials.gg
RecruitingNCT04141592Updated Nov 19, 2026

Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease

An observational study in Non-Alcoholic Fatty Liver Disease, sponsored by Queen Mary University of London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Queen Mary University of London · Observational

How we know

From the registry’s dates

  • Started Mar 2019; still recruiting 7 years 8 months later.
Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
153
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom — 17 open to participants now, 27 under way, 9 of them phase 3. Non-alcoholic Fatty Liver Disease · United Kingdom.

Planned enrollment
11th of 21
153 · median 153
Started
2019
with 11 others
Observational
21 of 122
5 open now
Primary completion
2027-07
later than 12 of 26 live
Registered
70th of 122
by date

Among the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, this one is the 11th largest by planned enrollment of the 21 observational ones that give a count, is one of 12 that started in 2019, is one of 21 observational ones, reaches primary completion later than 12 of the 26 other live ones, and was the 70th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

17 of the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease

Read the detailed description

In this study, the investigators will collect tissue, blood, stool, urine and saliva samples at the same time in order to enable a comprehensive disease phenotyping and ability to compare immunological, microbiological and metabolic features in patients with varying stages of NAFLD and healthy controls. To date there are limited published data evaluating simultaneously-obtained samples from adipose, gut and liver tissue and peripheral blood in NAFLD. The majority of participants in this study will be recruited from the bariatric surgery services enabling multiple tissue samples to be collected at time of surgery with minimal additional risk to participants.

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants will be identified from outpatient clinics of Bariatric, Gastroenterology, and Hepatology services at Homerton and King College Hospitals in addition to Gastroenterology outpatients from the Barts Health NHS Trust. Healthy control participants will be identified from patients undergoing outpatient assessment, gastroscopy or surgery for other non-malignant gastrointestinal disorders at hospital sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Confirmed non-alcoholic Fatty liver disease (diagnosed clinically, radiologically or histologically)
  • If diabetic, Diagnosed with Type 2 Diabetes Mellitus

OR

  • Healthy Control: no diagnosis of any liver condition including NAFLD

o NAFLD excluded by Fibroscan Controlled Attenuation Parameter (CAP) score of \<222 dB/m

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to give
  • Type 1 Diabetes Mellitus
  • Other form of liver disease (other than NAFLD)

    o Viral hepatitis, Auto-immune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, haemochromatosis, Sarcoidosis, cystic fibrosis, sickle cell disease

  • Taking medication associated with liver dysfunction (except methotrexate)
  • Auto-immune disease which in the investigator's opinion may confound immune profiling
  • Concomitant medications (except methotrexate, short course oral or inhaled corticosteroids)
  • Currently pregnant
  • Any major organ transplant (excluding corneal or hair transplant)
  • Regular alcohol intake greater than 14 units a week for female participants and 21 units a week for male participants
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
153 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Healthy Control

    non-obese individuals without fatty liver disease

  • Obese wihtout non-alcoholic steatohepatitis

    Body mass index greater than 30 without liver histological evidence of non-alcoholic fatty liver disease

    Procedure: Bariatric Surgery

  • Obese Non-alcoholic steatohepatitis

    Body mass index greater than 30 with liver histological evidence of non-alcoholic fatty liver disease

    Procedure: Bariatric Surgery

Interventions

  • ProcedureBariatric Surgery

    Already clinically indicated surgical procedures

    Also known as: Upper GI surgery

06

What researchers measure

Primary outcomes

  1. Impact of weight loss surgery upon Non-alcoholic steatohepatitis

    Proportion of patients developing resolution of NASH after weight loss surgery

    Time frame: Two years

Secondary outcomes

  1. Impact of weight loss surgery upon Non-invasive measures of fibrosis

    Evaluation of changes in liver transient elastography post weight loss surgery

    Time frame: Six months

07

Study locations

1 of 1 sites recruiting
  • Homerton University Hospital Foundation Trust
    London, Greater London E9 6SR, United Kingdom
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Jul 2027, 100 months after the start.

Of 160 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's planned 100 months is above that.

Counting every sponsor, half of 171 studies reached it within 49 months; a quarter within 24 and three quarters within 124.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jul 2026 → Jul 2027 and completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2019
First posted
Oct 28, 2019
StartActual
Mar 5, 2019
Primary completionEst.
Jul 31, 2027was Jul 2026
CompletionEst.
Jul 31, 2027was Jul 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2026→Jul 31, 2027
Nov 19, 2026
Study completion
Jul 31, 2026→Jul 31, 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Jul 31, 2026→Jul 31, 2027
    Study completion Jul 31, 2026→Jul 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04141592
Collaborators
Homerton University Hospital NHS Foundation Trust, Barts & The London NHS Trust, King's College Hospital NHS Trust
Responsible party
Sponsor
First posted
Oct 28, 2019
Start date
Mar 5, 2019
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

William Alazawi, MD Phd
Contact
w.alazawi@qmul.ac.uk
+442078822308
James Brindley, Md Phd
Contact
james.brindley@nhs.net
+442078827198
William Alazawi, MD Phd
principal investigator · Queen Mary University of London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion